Praveen Tipirneni, Morphic Therapeutic CEO

‘Dawn of oral ther­a­py’: Mor­phic touts UC da­ta in march to­ward Take­da’s En­tyvio

The ul­cer­a­tive col­i­tis R&D space is heat­ing up once again, as Mor­phic Ther­a­peu­tic tout­ed pos­i­tive mid-stage da­ta for its oral med.

At week 12, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.